Mary Jo LaDu Selected Research

Apolipoprotein E4

10/2022	APOE4 homozygote females are resistant to the beneficial effects of 17β-estradiol on memory and CA1 dendritic spine density in the EFAD mouse model of Alzheimer's disease.
1/2022	The detrimental effects of APOE4 on risk for Alzheimer's disease may result from altered dendritic spine density, synaptic proteins, and estrogen receptor alpha.
1/2022	APOE4 genotype or ovarian hormone loss influence open field exploration in an EFAD mouse model of Alzheimer's disease.
1/2020	Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How.
12/2019	Synergistic effects of APOE and sex on the gut microbiome of young EFAD transgenic mice.
10/2019	The role of APOE in transgenic mouse models of AD.
1/2017	EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease.
1/2016	Arabidopsis thaliana extracts optimized for polyphenols production as potential therapeutics for the APOE-modulated neuroinflammation characteristic of Alzheimer's disease in vitro.
1/2016	APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.
1/2016	The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mary Jo LaDu Research Topics

Disease

40	Alzheimer Disease (Alzheimer's Disease) 10/2022 - 06/2002
8	Inflammation (Inflammations) 02/2021 - 01/2004
7	Neuroinflammatory Diseases 01/2017 - 01/2004
5	Cognitive Dysfunction 01/2020 - 03/2003
3	Dementia (Dementias) 02/2021 - 08/2002
3	Amyloid Plaque 01/2017 - 01/2004
2	Obesity 02/2021 - 10/2019
1	Weight Gain 04/2021
1	Glucose Intolerance 04/2021
1	Type 2 Diabetes Mellitus (MODY) 02/2021
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 02/2021
1	Astrocytoma (Pilocytic Astrocytoma) 02/2021
1	Tauopathies 12/2018
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017
1	Neoplasms (Cancer) 01/2017
1	Hypersensitivity (Allergy) 01/2016
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2010
1	Memory Disorders (Memory Loss) 11/2010
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 11/2010

Drug/Important Bio-Agent (IBA)

20	Apolipoproteins E (ApoE)IBA 01/2020 - 01/2004
18	Apolipoprotein E4IBA 10/2022 - 01/2004
18	Amyloid (Amyloid Fibrils)IBA 01/2018 - 08/2002
15	ApolipoproteinsIBA 02/2021 - 06/2002
8	Apolipoprotein E3IBA 10/2019 - 01/2004
7	Amyloid beta-PeptidesIBA 01/2017 - 08/2002
7	Peptides (Polypeptides)IBA 05/2015 - 01/2011
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2004
4	Apolipoprotein E2IBA 01/2017 - 06/2002
2	Insulin (Novolin)FDA Link 04/2021 - 02/2021
2	Biological ProductsIBA 01/2020 - 03/2003
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 10/2014
2	Bexarotene (LGD1069)FDA Link 01/2017 - 10/2014
2	Amino Acids FDA Link 03/2011 - 01/2011
1	Estrogen Receptor alphaIBA 01/2022
1	Hormones (Hormone)IBA 01/2022
1	Liver X ReceptorsIBA 02/2021
1	Glucose (Dextrose)FDA LinkGeneric 02/2021
1	LipidsIBA 02/2021
1	Phospholipids (Phosphatides)FDA LinkGeneric 02/2021
1	CholesterolIBA 02/2021
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 02/2021
1	Sirtuin 1IBA 12/2018
1	neuronal pentraxinIBA 01/2018
1	Pharmaceutical PreparationsIBA 04/2016
1	PolyphenolsIBA 01/2016
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2016
1	LipopolysaccharidesIBA 01/2016
1	Retinoid X Receptors (Retinoid X Receptor)IBA 10/2014
1	Lipoproteins (Lipoprotein)IBA 10/2014
1	Protein Isoforms (Isoforms)IBA 01/2011
1	CytokinesIBA 11/2010
1	HDL LipoproteinsIBA 11/2010
1	ChemokinesIBA 11/2010
1	Presenilin-1IBA 11/2010
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 11/2010
1	Low Density Lipoprotein Receptor-Related Protein-1 (LDL-Receptor Related Protein)IBA 01/2004

Therapy/Procedure

5	Therapeutics 02/2021 - 11/2010
2	Oral Administration 04/2021 - 02/2021